Abstract
SARS-CoV-2, the virus responsible for the COVID-19 pandemic, is perceived to be primarily transmitted via person-to-person contact, through droplets produced while talking, coughing, and sneezing. Transmission may also occur through other routes, including contaminated surfaces; nevertheless, the role that surfaces have on the spread of the disease remains contested. Here we use the Quantitative Microbial Risk Assessment framework to examine the risks of community transmission of SARS-CoV-2 through contaminated surfaces and to evaluate the effectiveness of hand and surface disinfection as potential interventions. The risks posed by contacting surfaces in communities are low (average of the median risks 1.6×10−4 - 5.6×10−9) for community infection prevalence rates ranging from 0.2-5%. Hand disinfection substantially reduces relative risks of transmission independently of the disease’s prevalence and the frequency of contact, even with low (25% of people) or moderate (50% of people) compliance. In contrast, the effectiveness of surface disinfection is highly dependent on the prevalence and the frequency of contacts. The work supports the current perception that contaminated surfaces are not a primary mode of transmission of SARS-CoV-2 and affirms the benefits of making hand disinfectants widely available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Ana K. Pitol was supported by Swiss National Science Foundation (SNF)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval was needed for the study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data, models, and analyses are available at GitHub.
